Antiplatelet drugs in secondary prevention of stroke

International Journal of Clinical Practice

Volumn 52, Issue 2, 1998, Pages 91-97

  Diener, H C ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ARTICLE; BLEEDING; DEVELOPED COUNTRY; DISABILITY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0031911309     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Patrono C, Roth G. Aspirin in ischemic cerebrovascular disease: how strong is the case for a different dosing regimen? Stroke 1996; 27: 756-760.
2. ESPS Group (1987) The European Stroke Prevention Study (ESPS): principal end-points. Lancet 1987; ii: 1351-1354.
3. ESPS Group. European Stroke Prevention Study. Stroke 1990; 21: 1123-1130.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
5. Algra A, on behalf of the SPIRIT Study Group. SPIRIT: bleeding complications in patients after cerebral ischemia treated with anticoagulant drugs. Stroke 1997; 28: 231.
6. Atrial Fibrillation Investigators. Risk factors for stroke and the efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449-1457.
7. Cleland JGF, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Eur Heart J 1996; 17: 674-681.
8. Kistler JP, Robber AH, Martin JB. Cerebrovascular diseases. In: Isselbacher KJ, Braunwald E, Wilson J et al. Eds. Harrison's Principles of Internal Medicine, 13th edn. New York: McGraw-Hill, 1994; 2240-2256.
9. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
10. Patrono C. Aspirin as an antiplatelet drug. N Eng J Med 1994; 331: 1287-1294.
11. Hass WK, Easton JD, Adams HP Jr et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Eng J Med 1989; 321: 501-507.
12. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
13. American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: endpoint results. Stroke 1985; 16: 406-415.
14. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-331.
15. Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke 1994; 25: 1337-1341.
16. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337: 1235-1243.
17. Mayberg MR, Wilson SE, Yatsu F et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266: 3289-3294.
18. Diener H, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and aspirin in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
19. Gent M, Easton JD, Hachinski VC et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 192: 1215-1220.
20. Bonita R, Beaglehole R. Cerebrovascular disease: explaining stroke mortality trends. Lancet 1993; 341: 1510-1511.
21. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990; 21: 848-853.
22. Burn J, Dennis M, Bamford J et al. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25: 333-337.
23. Easton JD. Epidemiology of stroke recurrence. Cerebrovasc Dis 1997; 7(suppl): 2-4.
24. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-1845.
25. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994; 154: 1443-1448.
26. Busch M, Masuhr F, Einhäupl KM. Medical and surgical prevention of stroke: experiences around the world. Cerebrovasc Dis 1997; 1(suppl): 22-28.
27. Welty TE. Cerebrovascular disorders. In: Young LE, Koda-Kimble MA, Eds. Applied Therapeutics: The Clinical Use of Drugs. Vancouver: Applied Therapeutics Inc. 1995.
28. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatr 1991; 54: 1044-1054.
29. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266.
30. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-1349.
31. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatr 1996; 60: 197-199.
32. Dyken ML, Barnett HJM, Easton JD et al. Low-dose aspirin and stroke: 'It ain't necessarily so.' Stroke 1992; 23: 1395-1399.
33. Bousser MG, Eschwege E, Haguenau M et al. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
34. Muller TH, Su CAPF, Weisenberger H et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 179-186.
35. Diener H, Cunha L, Forbes C, Sivenius J et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
36. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 1430-1436.
37. Adams HP, Bendixen BH. Low-vs. high-dose aspirin in prevention of ischemic stroke. Clin Neuropharmacol 1993; 16: 485-500.